Cargando…

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

BACKGROUND & AIMS: Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1–F3 fibrosis. The primary objective of the BALANCED Cohort C was to assess the safety and tolerability of efruxifermin in patients with compensated NASH cirrhosis. METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrison, Stephen A., Ruane, Peter J., Freilich, Bradley, Neff, Guy, Patil, Rashmee, Behling, Cynthia, Hu, Chen, Shringarpure, Reshma, de Temple, Brittany, Fong, Erica, Tillman, Erik J., Rolph, Timothy, Cheng, Andrew, Yale, Kitty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832280/ https://www.ncbi.nlm.nih.gov/pubmed/36644237 http://dx.doi.org/10.1016/j.jhepr.2022.100563

Ejemplares similares

Generation of Affinity Purified Antibody Reagents for Specific Determination of Efruxifermin in Biological Matrices
por: Kinne, Adam S, et al.
Publicado: (2021)

ODP178 Development and Validation of a Noncompetitive Immunoassay Optimized for the Assessment of Pharmacokinetics of Biologically Active Efruxifermin in Humans
por: Hurst, Jacob, et al.
Publicado: (2022)

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
por: Tillman, Erik J., et al.
Publicado: (2022)

NASH‐related cirrhosis: An occult liver disease burden
por: Arrese, Marco, et al.
Publicado: (2017)

Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis
por: Türker, Fatih, et al.
Publicado: (2022)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Myeloma-associated systemic amyloidosis masquerading as NASH-associated cirrhosis and diabetic microvascular complications
por: Pal, Partha, et al.
Publicado: (2015)

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
por: McSweeney, Lorraine, et al.
Publicado: (2020)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
por: Zheng, Qianqian, et al.
Publicado: (2023)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2016)

Liver stiffness and thrombin generation in compensated cirrhosis
por: Dillon, Audrey, et al.
Publicado: (2019)

Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
por: Türker, Fatih, et al.
Publicado: (2021)

Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review
por: Farrugia, Marwin A., et al.
Publicado: (2023)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Small Bowel Abnormalities in Patients with Compensated Liver Cirrhosis
por: Aoyama, Taiki, et al.
Publicado: (2012)

Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2018)

Duodenal Permeability Is Associated With Mucosal Microbiota in Compensated Cirrhosis
por: Bloom, P.P., et al.
Publicado: (2022)

A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now
por: Cusi, Kenneth
Publicado: (2022)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Frequency of minimal hepatic encepalopathy in illeterate patients with compensated cirrhosis
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2016)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Compensated liver cirrhosis: Natural course and disease-modifying strategies
por: Kumar, Ramesh, et al.
Publicado: (2023)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
por: Hayashi, Momoko, et al.
Publicado: (2023)

Correction to “A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now”
Publicado: (2022)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
por: Abe, Kazumichi, et al.
Publicado: (2020)

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 1: compensated cirrhosis
por: Mansour, Dina, et al.
Publicado: (2023)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study
por: Buscail, Camille, et al.
Publicado: (2018)

Sleep Disturbance Is Associated With the Presence of Portosystemic Collaterals in Patients With Compensated Cirrhosis
por: Balakrishnan, Maya, et al.
Publicado: (2021)

Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
por: Thanapirom, Kessarin, et al.
Publicado: (2021)

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
por: Reiberger, Thomas
Publicado: (2021)

Short‐Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis
por: McGill, Mitchell R., et al.
Publicado: (2021)

Pregnancy Is Not Associated with an Increased Risk of Decompensation, Transplant, or Death in Compensated Cirrhosis
por: Mullin, Monica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gbo9ikmkj2fk3gsqq8d95b37d1